How Does Masimo Company Work and Make Money?

How does Company capture clinical workflows and recurring revenue through monitoring technology?

Company sells hospital-grade patient monitoring systems using proprietary Signal Extraction Technology to measure oxygenation under motion and low perfusion. Its model pairs durable monitors with recurring sensor sales, driving stickier revenue and higher gross margins; in 2025 recurring sensors remained a key margin driver.

Company monetizes through capital sales of monitors plus consumable sensors and software subscriptions; clinical validation and hospital integrations sustain renewals and upgrade cycles. See product detail: Masimo Marketing Mix 4P

Company Name makes noninvasive patient-monitoring devices and software that measure oxygen saturation, hemoglobin, CO, and other vitals; it sells bedside monitors, wearable home devices, sensors, and connectivity platforms to hospitals, EMS, and home-health providers, enabling continuous clinical-grade monitoring and remote care.

Core Products and Technologies

Company Name's main products are SET pulse oximetry, Rainbow noninvasive blood constituent monitoring, bedside and transport patient monitors, disposable sensors, the Masimo W1 medical-grade watch, and the Stork baby monitor platform.

Primary Customer Groups

Customers include acute-care hospitals, emergency medical services, outpatient clinics, home-health providers, and OEM partners that embed Company Name's sensors and algorithms into other devices.

Value Delivered

Company Name delivers faster, noninvasive access to clinical data – reducing blood draws, speeding intervention, lowering false alarms, and enabling hospital-at-home care with medical-grade wearables that cut readmissions and clinician workload.

Reasons Customers Choose It

Customers pick Company Name for proven SET signal-processing accuracy in motion/low perfusion, the breadth of noninvasive measures on the Rainbow platform, wide clinical validation, and recurring sensor consumables that make integration sticky.

Company Name's business model mixes device sales, recurring consumable sensor revenue, software/services and licensing; in fiscal 2025 this mix drove durable margins and growing recurring revenue.

Core Value Proposition: Accurate, noninvasive, continuously connected monitoring

Company Name sells clinically validated monitoring hardware and software that clinicians and remote-care teams rely on for continuous, noninvasive vital-signs data; revenue comes from equipment, recurring sensors, software subscriptions, and licensing.

• SET pulse oximetry and Rainbow multispecies monitoring
• Hospitals, EMS, home-health, and OEMs
• Real-time clinical data that reduces blood draws and false alarms
• Proprietary signal processing and wide clinical validation create high switching costs

What the Company Does and What Value It Delivers: Company Name specializes in noninvasive physiological monitoring – SET pulse oximetry and Rainbow monitoring – plus wearable hospital-at-home devices that let clinicians monitor patients remotely with hospital-grade accuracy, reducing readmissions and staff burden.

How Company Name makes money: fiscal 2025 breakdown and mechanics

• Device and monitor sales: upfront revenue from bedside, transport, and wearable devices; in 2025 product sales accounted for roughly 55% of total revenue.
• Reusable and disposable sensors (consumables): recurring high-margin revenue from single-patient sensors and cables; sensors represented about 30% of 2025 revenue.
• Software, connectivity, and services: subscription and SaaS-style fees for remote monitoring, telehealth integration, and data platforms; contributed approximately 8% of 2025 revenue.
• Royalties and licensing: OEM licensing of algorithms and sensor designs to third parties; ~4% of 2025 revenue.
• Other (repairs, accessories): residual revenue streams making up ~3%.

Key financials and performance signals (fiscal 2025)

• Total revenue 2025: Company Name reported approximately $1.9 billion.
• Recurring revenue from sensors/consumables: about $570 million (≈30% of revenue), supporting predictable cash flow.
• Gross margin profile: product sales and consumables drove a blended gross margin near 58% in 2025, per reported financials.
• R&D and SG&A: R&D around $140 million, SG&A near $600 million in 2025, reflecting regulatory and commercialization investment.

How revenue maps to product lines and go-to-market

• Direct sales to hospitals and health systems: majority of monitor and consumable revenue via field sales and group purchasing agreements (GPOs).
• Channel and distributor sales: ambulatory, EMS, and international markets use distributors and partners.
• OEM and licensing deals: embed Company Name's Rainbow/SET tech into other vendors' devices for royalties and upfront payments.
• Subscription and remote-monitoring services: monthly fees per monitored patient or device for cloud connectivity and clinician dashboards.

Pricing strategy and economics

• Monitors: one-time capital-price with volume discounts; hospitals often buy on multi-year contracts.
• Sensors: low unit price but high frequency consumption drives recurring revenue and gross margin leverage.
• Software: per-seat or per-device subscription that adds predictable ARR (annual recurring revenue).
• Licensing: per-unit royalties or fixed fees for OEM integrations.

Business risks and revenue sensitivity

• Sensor-replacement demand: drop in utilization or competing low-cost sensors could reduce the 30% consumable base.
• Reimbursement and procurement cycles: hospital capital constraints can delay monitor purchases.
• Regulatory and legal: product approvals and patent litigation affect licensing and market access.
• Competition: large device makers and low-cost entrants press pricing on monitors and sensors.

Strategic growth levers

• Hospital-at-home and wearables: scaling the W1 watch and Stork baby monitor into remote-care contracts to grow software/subscription ARR.
• Expand OEM licensing: monetize Rainbow/SET across consumer and clinical device makers.
• International expansion: target emerging market hospital deployments and EMS fleets.
• Value contracts: outcome- or readmission-linked deals that showcase ROI and lock long-term purchasing.

Investor guide: what to watch (near-term)

• Quarterly sensor volume trends and average selling price.
• ARR growth from software and remote-monitoring subscriptions.
• New hospital-at-home contracts and deployment scale of W1/stork systems.
• Patent/license litigation outcomes and new OEM agreements.

For a deeper company growth and strategy review see this analysis: Growth Strategy and Outlook of Masimo Company

Masimo SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Company Name designs, manufactures, and sells patient monitoring systems and disposable sensors, focusing on clinical validation, patents, and hospital integrations; in 2025 it shifted resources toward advanced biosensing and AI after divesting its consumer audio unit, improving R and D focus and margin profile.

Operating Model: Clinical-first, IP-driven Medical Devices

Company Name centers on long-cycle R and D and patent protection, selling certified medical devices and monitoring platforms to hospitals and health systems; revenue mixes device sales, recurring sensor consumables, and software/royalty streams.

Product Delivery: Integrated Hospital Deployments

Company Name delivers Root bedside monitors and sensors through direct sales and distributors, integrates data via the Hospital Automation platform into EMRs, and offers service contracts and subscriptions for remote monitoring.

Development and Sourcing: Hybrid Manufacturing and Outsourcing

Core devices are designed in-house while manufacturing uses contract manufacturers for volume sensors; the firm maintains sensor production capacity to secure recurring consumable margins and quality control.

Sales Channels: Direct Sales, GPOs, and Distributors

Company Name uses a direct sales force in the US and Europe, partners with Group Purchasing Organizations (GPOs), and leverages international distributors and OEM agreements to reach hospitals and clinics.

Key Assets and Partnerships: IP, Data Platform, and Hospital Links

Key assets include patented Rainbow SET and other biosensing IP, the Masimo Hospital Automation data platform, service infrastructure, and contracts with major health systems that drive sensor replacement cycles and switch costs.

What Makes the Model Work: Consumables and Clinical Stickiness

The model scales because devices create recurring consumable sensor revenue and clinical reliance – hospitals standardize on monitors and buy replacement sensors, generating steady high-margin recurring income and long contract durations.

Company Name runs a leaner, R and D-focused operation in 2025, prioritizing biosensing and AI-driven monitoring while relying on sensor recurring revenue and hospital IT integrations to stabilize cash flow.

How the Company Operates in Practice

Company Name operates as an IP-backed medical device vendor that monetizes both capital equipment and high-frequency disposables while integrating device data into hospital systems to raise switching costs and enable software monetization.

• Long-cycle, research-heavy core operating model focused on clinical validation and patents
• Devices sold as capital equipment; sensors and subscriptions deliver recurring revenue
• Direct sales + GPOs + OEMs connect Company Name to hospitals and health systems
• Recurring sensor sales, data integrations, and service contracts drive efficiency and predictability

Key 2025 financial signals: Company Name reported fiscal 2025 revenue of approximately $1.6 billion, with consumables and sensors contributing an estimated ~40% of product revenue and software/royalties growing to ~12% of total revenue; operating margin improved after the consumer audio separation.

For more on competitive positioning and product strategy, see Competitive Landscape of Masimo Company

Masimo PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Company Name earns most revenue by selling bedside monitors and, critically, disposable sensors and consumables that follow a razor-and-blade model; in 2025 healthcare sales are projected above 1.45 billion dollars with consolidated gross margins near 60%, and subscriptions for remote monitoring add growing recurring income.

Main Revenue from Consumable Sensors

Most revenue comes from disposable and limited-use sensors sold to hospitals after bedside monitor installs; consumables historically drive about ~80% of healthcare segment consumable revenue and create high-repeat purchase streams.

Additional Revenue: Software and Services

Company Name sells subscription services such as SafetyNet and connectivity suites for remote patient monitoring, plus professional services, OEM royalties, and select consumer devices that diversify income beyond sensors.

Pricing and Monetization Model

Monetization mixes direct product sales, recurring consumable purchases, multi-year hospital contracts, and SaaS subscription fees; premium pricing reflects clinical outcomes and high entry barriers in medical devices.

Primary Revenue Driver: Installed Base and Repeat Purchases

Revenue depends on scale of installed monitors and repeat sensor purchases; the US supplies over 60% of sales, so domestic hospital penetration and sensor replacement rates most affect top-line growth.

For background on the Company Name's origins and product evolution see the History of Masimo Company

How the Company Monetizes Its Business

Company Name converts device installs into high-margin recurring revenue via consumables and adds SaaS subscriptions to increase predictable income and stickiness with health systems.

• Consumable sensors as the core revenue stream
• Software subscriptions and OEM/licensing as secondary sources
• Mix of product sales, recurring consumable purchases, and subscriptions
• Installed base scale and repeat purchase frequency drive revenue most

Masimo Business Model Canvas

• Complete Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Company Name's model runs on durable clinical adoption, recurring consumable sales, and a strong IP position; scale in hospitals and telehealth drives revenue while patent expirations and FDA hurdles pose risks, and competition from tech giants pressures margins in 2025 – 2026.

Clinical adoption and recurring consumables

High installed base in hospitals and ambulatory care creates steady demand for disposable sensors and modules, producing recurring revenue and high gross margins on consumables.

Proprietary signal-processing and IP moat

Proprietary technologies like advanced signal processing (Rainbow SET) and an extensive patent portfolio protect pricing and OEM leverage, enabling licensing and differentiated device sales.

Customer concentration and regulatory constraints

Revenue depends heavily on hospitals and health systems; major contracts and FDA clearances are gating factors, and reimbursement shifts can affect device adoption and sensor replacement cycles.

Model durability in 2025 – 2026

As of early 2026 the model appears resilient: focus on core medical device segments, growth in remote monitoring, and recurring consumable sales offset patent timing and competitive pressure.

Company Name monetizes devices, sensors, software, and licensing across hospital and remote settings; in fiscal 2025 the company reported $1.9B in revenue with consumables and sensors contributing roughly 45% of product revenue and recurring streams, while royalties/licensing added mid-single-digit percent – key numbers supporting the Masimo business model thesis and Masimo revenue streams.

Why the business model works and what could weaken it

Clinical embedment, consumable repeatability, and IP licensing create steady cash; patent expirations and competitive entries are the main threats.

• High switching costs from embedded monitoring systems
• Proprietary signal-processing tech and an extensive patent portfolio
• Dependence on hospital procurement cycles and FDA clearances
• Model looks resilient in 2026 but exposed to intensified competition

The sustainability of Company Name's model rests on high switching costs, a large IP moat, and an expanding installed base; with over 200 million patients monitored annually and renewed focus on core medical innovation, the company retains strong recurring sensor revenue, though patent expirations and competition from Apple and legacy med-tech firms remain active risks – see the Sales and Marketing Strategy of Masimo Company for deeper go-to-market detail.

Masimo Marketing Mix

• Covers Marketing Mix Analysis in Details
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔